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Abstract
Diabetes is a chronic incurable disease of high prevalence in older people due to changes in glucose
homeostasis, diabetes-related complications and other comorbidities that affect physical and cognitive functioning
and have implications for medicines use. Polypharmacy is common and represents a significant medicine and self-
care burden, risk of medicine-related adverse events, and inappropriate prescribing. Some medicines used to treat
diabetes such as insulin, sulphonylureas, warfarin and antiplatelet agents are known as ‘high risk’ medicines
because of their association with adverse events.
Managing medicines is a complex process that requires particular knowledge and skills and strategies to
proactively identify risks and plan care to reduce the risk such as following evidence based recommendations/
guidelines, comprehensive assessment and monitoring, using decision support tools such as BEERs, STOPP and
START criteria, and importantly, involving the individual and/or carers in medicine decisions to personalise
medicines education and the medicine regimen.
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Introduction and Background to Diabetes
Diabetes is a chronic incurable disease of high prevalence in older
people [1]. Most older people have type 2 diabetes (T2DM), some have
long standing type 1 diabetes (T1DM) and some develop Latent
Autoimmune Diabetes in Adults (LADA). T2DM is associated with
loss of first phase insulin release and progressive loss of beta cell
function; consequently insulin production gradually declines. Both
changes contribute to hyperglycaemia. Insulin resistance and elevated
postprandial blood glucose are features of overweight older people
with T2DM [2]. Initially these people might benefit from Metformin
and/or other glucose lowering medicines (GLM) but most eventually
require insulin [3]. Lean older people usually require insulin soon after
diagnosis, especially if they have significant weight loss and ketosis [2].
The changes in glucose homeostasis and in the counter-regulatory
response to hypoglycaemia as well as other diabetes- and age-related
changes such as declining renal and liver function and nutrition
deficits influence medicine safety and medicine choices [3]. Long
duration of diabetes is associated with complications that usually
require medicines. However, increasing age and diabetes
complications and their associated physical and cognitive functional
changes complicates medicines management, especially medicines
self-management and increase the self-care burden [3,4].
Despite their commonalities, older people with diabetes are highly
individual: that is they are not a homogeneous group. Consequently,
diabetes care, including the medicines regimen, must be designed in
collaboration with the individual (presonalised) and when appropriate
with their family carers [3,4,5]. The individual‘s health and functional
status, social situation, health and general literacy, and available
support from family and/or the community are important
components of a comprehensive medicine assessment.
Older People with Diabetes and Medicine-Related
Vulnerability
Prescribing in older people is a balance between managing
conditions according to disease-based guidelines and addressing the
patient’s goals while at the same time avoiding medicine-related
problems (Phillippa Binns).
Medicine-related problems are common in older people and are
associated with increased costs, hospital admissions and poor
outcomes and recovery takes longer [6]. Over 60% of hospital
admissions for medicine-related adverse events (AE) involve warfarin/
antiplatelet agents, insulin and other GLM alone or in combination:
many are preventable [6]. For example, Gurwitz et al. [7,8] suggested
27% of adverse medicine-related events in primary care and 42% in
long term care could have been prevented. Most of the problems occur
during prescribing and monitoring. Medicine errors and AEs are
associated with falls, delirium, geriatric syndromes, confusion,
incontinence and frailty and death [7,8,9]. Common errors include
prescribing inappropriate medicines and/or inappropriate doses
(under and overprescribing) and not reducing doses as renal and liver
function declines. Both under and overprescribing can result in AEs
[10].
Over prescribing GLMs or GLM doses can cause hypoglycaemia;
under prescribing contributes to hyperglycaemia, although the
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underlying causes of both states are multifactorial. Hyperglycaemia is
often not regarded as a medicine side-effect or AE in older people,
particularly in aged care homes (ACH) [9]. Hyperglycaemia has
significant short term effects on memory and cognition and causes
fluid and electrolyte changes that predispose T1DM to ketoacidosis
and T2Dm to hyperosmolar states (HHS): both these states have
serious consequences including death. In the longer term,
hyperglycaemia causes damage to tissues and organs and exacerbates
existing diabetes complications, other comorbidities and the ageing
process [11].
Older people living in ACH are among the most vulnerable
members of the population. Forty precent of older people in ACHs
and 20% living in the community are prescribed at least one
inappropriate medicine [9]. The focus in ACHs is often on
administering medicines, which is a challenging and time consuming
task for staff, especially given the staffing and resource issues in many
ACHs. Other key medicine-related activities are often suboptimal, for
example not timing GLM doses to correspond with meals and not
timing blood glucose tests to the GLM action profile.
The Imperative for Pharmacovigilance
It is impossible to separate the chance of good from the risk of ill
(David Hume).
Managing medicine is complex. Many health professionals often
focus on prescribing and administering medicines and patient non-
adherence to medicines. Inappropriate prescribing including
prescribing potentially inappropriate medicines (PIMS) for older
people is common [12-14]. PIMS are still prescribed as first line
management for vulnerable people even when evidence suggests their
use leads to poor outcomes [15,16]. Many PIMS are appropriately
prescribed according to individual needs at the time. The issue is that
they are often not stopped when the acute episode resolves. If PIMs
were stopped when they are no longer required many unintended
consequences could be avoided. Usually, the risks associated with
PIMS outweigh the benefits, especially when safer options are
available. In some cases a safer option could be a non-medicine option;
for example, Cognitive Behavioural Therapy (CBT) or acupuncture to
manage pain.
As mentioned, medicine-related AEs are common reasons for
hospital admissions. Many PIMs and medicines that are actually
inappropriate (AIM) are prescribed during the hospital stay, often in
intensive care units (ICU) [12,13]. Older people who survive ICU
frequently experience polypharmacy, have several transitions to other
wards/units during an admission, and are at high risk of AEs after
discharge [12]. Morandi et al. [12,13] found 85% of older ICU
survivors were discharged from hospital on one or more PIMs and >
50% were discharged with one or more AIM.
It is important to acknowledge the medicines may have been
appropriate choices in the acute phase of the illness and responses to
medicines are closely monitored in ICU, but the medicines may not be
appropriate when the illness resolves. This scenario highlights the
essential need to constantly review the medicine regimen when health
status fluctuates and for proactive medicine reconciliation. Commonly
prescribed PIMs are opioids, anticholinergics and antidepressants,
which cause confusion, cognitive impairment and falls. These doses
and dose frequency of these medicines are likely to be inappropriate at
discharge [12,13,15].
People over age 65 use more medicines than any other age group:
90% use at least one medicine and 50% use ≥ 5 medicines [17]. A point
prevalence survey in our hospital in Geelong, Australia suggests older
people with diabetes use an average of 7 medicines in multiple doses
throughout the day: range 1–17 [18]. In addition, they frequently use
1–5 complementary medicines especially vitamin and mineral
supplements [14,18]. Thus, polypharmacy represents a significant
medicine self-care burden and is common for many older people with
diabetes. It is also associated with increased health care costs [19].
Polypharmcy is defined in various ways, but the term usually refers
to using > 5 medicines concurrently; however it is also defined as older
people ‘taking multiple unnecessary medicines’ [20]. The term has
negative connotations because of the associated risk of medicine errors
and AEs. Diabetes-related polypharmacy usually evolves over time due
to the progressive nature of T2DM and the development and
progression of diabetes complications that require medicines.
Evidence shows that polypharmacy represents a major AE risk after
discharge from hospital [9]. Box 1 outlines common causes of
polypharmacy.
Box 1: Some key factors that contribute to polypharmacy
• Lack of knowledge on the part of the prescribers and the
individual for whom the medicine/s was prescribed.
• Increasing age because the progressive nature of T2DM, diabetes
complications and other comorbidities that affect physical,
cognitive and sensory function and usually require medicines.
• Older people who self-diagnose and self-medicate using non-
prescribed medicines, medicines prescribed for a previous illness
or another person, and complementary medicines.
• Prescribing cascade where medicines are prescribed to manage
symptoms rather than the underlying cause of the symptoms
and/or not stopping unnecessary medicines.
• Inadequate communication among health professional carers and
with the individual that contributes to the prescribing cascade,
especially if medicine reconciliation is not undertaken.
• Inappropriate/inadequate assessment and clinical monitoring.
• Admission to hospital, especially ICU, and transfer among care
settings.
Because of the multifactorial metabolic derangements that need to
be managed, one could argue that polypharmacy could actually be best
practice for some people with diabetes. However, as the number of
medicines increases, the likelihood of PIMS and AIMs being
prescribed also increases [19] and the risks outweigh the benefits
because older people have increased susceptibility to medicine side
effects and are more likely to develop medicine toxicity than younger
people [19].
It is possible that the prescribing cascade that leads to PIM/AIM
prescription occurs when prescribers do not consider whether a new
medicine is needed, whether some existing medicines could be
stopped, especially if they are PIMS/AIMs or whether a non-medicine
option is a safer and equivalent choice. Several age-and diabetes-
related changes affect medicine safety and the risk/benefit ratio and,
therefore, need to be considered when making medicine choices [11],
(Table 1)
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Issue Possible consequences
Polypharmacy, which is common in older people with diabetes Medicine-medicine interactions and food-medicine interactions.
Risk of prescribing potentially inappropriate medicines (PIMS) and actually
inappropriate medicines (AIMs) especially when multiple prescribers are involved.
Risk of presentation to emergency department/admission to hospital.
Medicine self-management burden and non-adherence that may make medicines
more or less effective but could reduce some potential adverse effects
Age- and diabetes-related effects on the gastrointestinal system
Autonomic gastric neuropathy
Under and over nutrition
Changed appetite, dysphagia
Malabsorption—food and medicines
Reduced gastric acid production
Reduced saliva production
Nausea and vomiting
Reduced appetite due to age and some medicines increase the risk of
hypoglycaemia and further reduce the already compromised ability to mount a
counter-regulatory response to hypoglycaemia.
People over 70 years often have nutritional deficits such as low protein stores
(muscle mass), and vitamin D, B 12, C, E and calcium, and magnesium deficits
Weight loss may not be appropriate in overweight older people because of the
associated loss of muscle mass and strength and the risk of sarcopenia and
associated falls risk, .
Some oral glucose lowering medicines stimulate appetite, which may be positive
for some older people.
Nausea, vomiting and bloating may impair medicine absorption from the gut;
alternatively it can be a side effect of many medicines and/or illnesses.
Using medicines that delay or increase absorption of medicines or nutrients from
the gut when the individual has existing gastrointestinal comorbidities for example:
antacids and Metformin, which reduces vitamin B12 absorption in some
individuals; antibiotics and Phenytoin reduce folic acid absorption; corticosteroids,
thiazide diuretics and some antipsychotic medicines contribute to hyperglycaemia.
Hyperglycaemia, protein deficits and weight loss lead to low serum protein and
body water, which affects medicine binding, consequently more free medicines
are in the circulation.
Weight gain and increased deposition of body fat leads to increased storage of
fat-soluble medicines and delayed elimination resulting in unpredictable action
profiles.
Difficulty swallowing some medicines, which can lead to non-adherence or
inappropriate medicine crushing.
Difficulty distinguishing hyperglycaemia-related dry mouth from medicine side
effects.
Increase risk of some medicines damaging tooth enamel.
High fibre diet can increase gut transit time and reduce medicine absorption.
Enteral and supplementary feeds may be needed if the individual has swallowing
difficulties or is frail.
The medicine dose form may need to be changed e.g. large sized tablets that are
difficult to swallow and medicines that should not be crushed because they irritate
the gut and their action profile will be changed.
Reduced renal function
Increased renal threshold for glucose
Compromised renal function leads to reduced medicine clearance and more
circulating medicine in the blood.
Renal anaemia.
Risk of kidney damage with some medicines including complementary medicines
and investigative procedures involving radio contrast media.
Microalbuminuria is associated with dementia, which inhibits medicine self-care
and decision-making and increases hypoglycaemia risk.
Macroalbuminurea predicts hypoglycaemia.
HbA1c is less reliable in the presence of renal disease and anaemia.
Dialysis might be needed in end stage renal disease.
Glucose urine tests are unreliable.
Urine glucose testing is not appropriate to detect hypoglycaemia
Liver damage is common in older people Reduced metabolism of some medicines.
Monitor liver function.
Reduced cardiac output and reduced peripheral blood flow Delayed medicine transport to target tissues, therefore delayed action and
effectiveness
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Silent MI and sudden death Increased medicine in the circulation and longer duration of action.
Fluid retention, which affects medicine uptake in the tissues.
Hypoglycaemia precipitates cardiac events such as MI and arrhythmias, which are
secondary to autonomic activation of the counter-regulatory response to low blood
glucose and results in haemodynamic changes, vasoconstriction, intravenous
coagulability and viscosity.
Inadequate, inappropriate support from others Isolation, people who have limited social contact and support are more likely to
become depressed and non-adherent to the management plan, particularly
medicines.
Reduced intake.
Table 1: Issues that can influence prescribing, administering and monitoring glucose lowering medicines in older people with diabetes and some
possible consequences.
Some Common Medicine-Related Issues in Older
People
Many older research trials do not include older people or only
include relatively healthy older people and those using none or one
medicine, thus it is difficult to generalise the findings to frail older
people. [3]. Excluding older people from clinical trials is not a new
phenomenon [21]. There is strong evidence that many medicines
commonly prescribed for older people should be used with caution or
not prescribed [9,15,16,22,23]. Table 2 outlines some medicines
commonly used to manage diabetes in older people and their
associated risks.
GLM class Associated risk Comments
Metformin is often considered to be
first line therapy for overweight
people with T2DM.
Gastrointestinal disturbances are common.
Anaemia due to reduced absorption of vitamin B12.
Lactic acidosis is rare. It is a normal adaptive physiological
response but if the compensatory response is overwhelmed lactate
accumulates and acidosis can occur.
Start at a low dose and slowly titrate to reduce
gastrointestinal effects.
Reduce the dose if creatinine clearance 30–60
mL/min and use with caution or cease if it is < 30 mL/
min.
Sulphonylureas Hypoglycaemia especially with long acting medicines e.g.
Glibenclamide, which has been withdrawn from the market in some
countries.
Hypoglycaemia risk increases with increasing age due to changed
counter regulatory response to low blood glucose and
predominance of neuroglycopenic symptoms, which can be
mistaken for confusion, delirium and other cognitive deficits.
Some blunt myocardial preconditioning
Increased appetite.
Hypoglycaemia contributes to falls risk, cognitive
impairment in the short term (working and delayed
memory) and dementia in the long term.
Increased appetite might be appropriate in some
older people.
Long acting formulations such as Diamicron MR
should not be crushed for administration.
It is important to avoid hypo and hyperglycaemia, the
blood glucose target range should be individualised
But generally 6–15 is safe unless the person has
hypoglycaemic unawareness.
HbA1c targets should also be individualised
considering functional status:
Functionally independent:7–7.5% (53–57 mmol/mol)
Functionally dependent 7.5–8% (53–64 mmol/L)
Frail and/or dementia up to 8.5% (up to 70 mmol/
mol).
Meglitinides Rapid insulin release and short duration of action.
Low hypoglycaemic risk.
May be useful in older people but are not subsidised
in some countries.
Thiazolidiones (TZD) Peripheral oedema
Myocardial infarction (Rosiglitazone increases LDL-c)
Heart failure risk
Congestive cardiac failure
Weight gain
Reduce white and red blood cell count
Worsens macular degeneration
Risk of bladder cancer with Pioglitazone
Contraindicated in New York Heart Foundation heart
disease grades 3 and 4 and in the presence of
oedema.
Could reduce liver function. Test liver function before
commencing and at regular intervals while on TZDs.
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Fractures in the extremities especially in women
Glucagon-Like Peptide-1 (GLP-1) Flatulence and bloating and other gastrointestinal disturbances.
Nausea.
Long tem risk of pancreatitis
Induce weight loss in some people.
Not extensively studied in older people, consequently
more research is needed in older people.
Might improve cardiovascular risk by reducing
triglycerides and low density lipoprotein (LDL)
Weight loss might not be desirable in frail older
people.
Low risk of hypoglycaemia unless combined with
some Sulphonylureas or insulin.
Injectable form may not be acceptable to some older
people.
Dipeptidyl peptidase 4 (DPP-4) Flatulence
Gastrointestinal disturbances
Not extensively studied in older people, consequently
more research is needed in older people.
Low risk of hypoglycaemia unless combined with
some Sulphonylureas or insulin. But DPP-4 agents
delay gastric emptying, which delays glucose entry
into the blood stream, thus if hypoglycawmia does
occur it can be prolonged.
Low risk of medicine interactions: Saxagliptin has the
highest risk.
Sodium/glucose cotransporter-2
(SLGT-2)
Urinary tract and genital infections
Polyuria in volume sensitive people
Some agents are less effective in the presence of renal impairment
More research is needed in older people.
Insulin
Short
Rapid
Long acting analogues
Premixed
All are associated with hypoglycaemia risk. Some represent greater
risk than others
Long acting analogues cannot be mixed with other
insulin
They have a lower hypoglycaemia risk than many
other insulins. Health professionals need to
understand the action profile of each insulin class to
prescribe safely and monitor approiately.
Older people often require insulin because of
progressive beta cell loss
Sliding insulin scales to manage hyperglycaemia is
contraindicated
Can be administered using insulin pens, syringes,
insulin pumps and continuous infusions in acute
settings e.g. HHS
Table 2: Commonly used glucose lowering medicines (GLM), antihypertensive and lipid lowering medicine classes and their related risks. Some
commonly prescribed GLMs are classified as high risk medicines e.g. insulin. Healthy diet and exercise are still necessary even when medicines
are needed.
Key issues include:
Hypoglycaemia is a significant risk with insulin and some
sulphonylureas, especially long acting preparations [2,15,16,24]. Older
people with both T1DM and T2DM are particularly vulnerable to
hypoglycaemia: it is the most frequent metabolic complication in older
people and may account for one in five hospital admissions in older
people with diabetes aged 80 years and older [25]. The GLM
prescribed, often the long acting sulphonylurea glibenclamide, may
have been inappropriate in a large number of people who had
dementia and/or renal failure in Greco et al’s study [25].
Hypoglycaemia is associated with longer hospital stay and increased
costs in T2DM [26]. It is often difficult to detect in older people
because neuroglycopaenic symptoms predominate and can be
misinterpreted for confusion and not treated. Significantly,
hypoglycaemia is associated with short term changes in delayed and
working memory [27] and dementia in the longer term [28, 29] and
can precipitate myocardial infarction [30], which might be ‘silent’
(present with atypical symptoms). The ability to mount a counter-
regulatory response to hypoglycaemia declines over time and the
glucagon response is virtually absent in many older people [26] and
when the individual is malnourished and has limited glucose stores.
Macroalbuminuria predicts severe hypoglycaemia [31]. Common
causes of hypoglycaemia are shown in box 2.
Box 2: Hypoglycaemia risk factors in older people
• Age.
• Prescribed GLMs especially some sulphonylureas and/or insulin.
• Long duration of diabetes, which is associated with progressive
changes in the counter-regulatory response to hypoglycaemia, in
particular diminished secretion of glucagon and growth hormone,
which contributes to hypoglycaemia unawareness.
• ‘Tight’ blood glucose control.
• Renal and liver disease.
• Nutritional deficits.
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• Cognitive impairment and dementia, which make it difficult for
the individual and health professionals to recognise
hypoglycaemia.
• Multiple diabetes complications and other comorbidities that
cause functional deficits and compromise diabetes-self care.
• Most current hypoglycaemia education programs and policies are
not tailored for older people e.g. the focus on adrenergic
hypoglycaemia symptoms such as sweating and trembling when
neuroglypaenic symptoms such as confusion and behaviour
change are more common in older people and contribute to
hypoglycaemic unawareness.
• History of severe hypoglycaemia.
If health professionals, the person with diabetes or family carers do
not consider medicine side effects as the cause of symptoms,
medicines can be prescribed to treat the symptom (prescribing
cascade) and increase the likelihood of adverse events. Determining
the cause of symptoms can be difficult because they are often non-
specific and atypical.
Declining renal function and chronic kidney disease is common in
older people with diabetes and is a predictive risk factor for medicine
AEs [24] especially hypoglycaemia and falls [11]
Antipsychotic medicines when they are prescribed to manage
behavioural problems associated with dementia.
Antihypertensive medicines that carry risk of postural hypotension
and can lead to falls.
Some lipid lowering agents are contraindicated if liver disease is
present. Liver function declines with age. Therefore, monitoring liver
function is an important aspect of medicine management.
Sliding insulin scales to manage hyperglycaemia [15, 16]. Sliding
insulin scales might lower the blood glucose, but they do not address
the preceding factors that led to hyperglycaemia such as infections
(urinary tract, foot infections), diet, stress, pain, depression that need
to be treated otherwise hyperglycaemia could lead to hyperosmolar
states (HHS), confusion, delirium, falls, reduced quality of life and
symptomatic discomfort [4,15]. That is, it is essential to treat the cause
rather than just reacting to the symptom, hyperglycaemia. For these
reasons the trend is not to use sliding insulin scales in routine care,
although they may still be indicate in acute illnesses such as DKA and
HHS in an insulin infusion.
Blood glucose is often tested infrequently in ACHs and/or the
testing schedule is not related to key medicine safety factors such as
meal times and glucose lowering medicine action profiles, especially
peak action times for insulin.
Many medicines prescribed to manage diabetes and its
complications are classed as high-risk medicines because of their side
effects and the way they are used and metabolised in the body, for
example insulin and anticoagulants [32]. High risk medicines have a
significant risk of causing catastrophic harm when used in error.
However, as the information presented so far shows, high risk
medicines can also cause significant harm when used appropriately if
their effects are not monitored closely and when the dose and/or dose
regimen is not safe for the individual.
Box3: Examples of some commonly prescribed medicines that can
increase or lower blood glucose. Medicine availability changes as older
medicines are discontinued or removed by regulatory authorities. The
information in this box was current at the time of publication.
Detailed information can be obtained from:
• http://www.diabetesincontrol.com/tools/tools-for-your-practice/
9625-drugs-that-can-affect-blood-glucose-levels
• Medicines that increase blood glucose are known as diabetogenic
medicines. Diabetogenic medicines also increase blood glucose in
older people at risk of diabetes. Some of these medicines are PIMs/
AIMs but they may be appropriate treatment for the individual’s
illness at the time. The individual and their carers should be
informed about the potential effect on blood glucose when
medicines that increase blood glucose are commenced and what to
do if the blood glucose is affected. Blood glucose monitoring is
useful to detect changes early. Medicines should be used at the
lowest effective dose for the shorted possible time and in the least
diabetogenic dose form. It is important to manage the
hyperglycaemia to reduce the associated risks such as dehydration,
delirium, falls, incontinence and candida infections e.g.
corticosteroids. Examples include:
• Corticosteroids especially long acting oral preparations.
• Antipsychotics especially atypical antipsychotics.
• Sympathomimetics such as adrenaline and salbutamol.
• Thyroid and growth hormones.
• Thiazide diuretics.
• Some antihypertensive medicines such as atenolol, carvedilol and
metoprolol.
• Some herbal medicines such as Chrysanthemum extract, Honey
bee pollen, Tamarind. Note: people generally use these medicines
to treat intercurrent illnesses not to manage blood glucose.
Significantly, most of the information is based-on single case
reports, which do not provide the botanical names of the herbs in
the medicine.
• Medicines that lower blood glucose in addition to GLMs
Determine the individual’s hypoglycaemia risk before
commencing medicines that can increase the hypoglycaemia risk
or mask hypoglycaemia symptoms. The individual and their carers
should be informed about the potential effect on blood glucose
when medicines that increase blood glucose are commenced and
what to do if the blood glucose is affected. Blood glucose
monitoring is useful to detect changes early. Examples include:
• Sulphonamides
• Salicylates
• Warfarin
• MAO inhibitors
• Tuberculostatics.
• Herbal medicines that can lower the blood glucose include Aloe,
Ginseng, Momordica charantia (Bitter melon), Trigonella foenum
graecum (Fenugreek) and Opuntia species (prickly pear) especially
if they are combined with conventional GLMs. Note: there is some
reasonable quality research to support the glucose lowering effects
of these medicines.
• Alcohol.
• Note: some medicines can cause either hyop- or hyperglycaemia
e.g. magnesium salicylate, Lithium, Lanreotide.
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Strategies that can to Improve Medicine Safety and
Reduce Medicine-Related Adverse Events in Older
People with Diabetes
Who assess well, treats well (Fundamenta Medica).
Regular comprehensive medicine assessments and medicine
reconciliation are essential, especially when several doctors prescribe
medicines for the same person [24]. A medicine assessment must
include information about the individual’s medical and medication
history, health status, physical functioning as such as Activities of
Daily Living (ADL) Instrumental Activities of Daily Living (IADL)
Geriatric Discussion Scale, cognitive function such as Mini Mental
State Examination (MMSE) and sensory status (vision and hearing),
social circumstances and available support, especially if the individual
lives in the community. Home medicines reviews can elicit important
information about the social factors that affect medicine self-
management.
Medicine assessments should aim to identify key related risks such
as PIMs/AIMs, duplicate prescriptions, and CAM and over-the-
counter (self-prescribed) medicine use, hypoglycaemia,
hyperglycaemia, other adverse events, falls, pain, and self-care
capacity. It is essential to maintain up-to-date medicine histories and
medicine lists and communicate any changes to everybody involved in
the individual’s care, the individual and his or her family carers in a
timely manner and using appropriate language and design/format for
written material.
As indicated, it is important to monitor liver and renal function,
which decline with increasing age: most people over age 60 have liver
and renal function changes [33]. These changes affect medicine
choices. It is important to stop or reduce the doses of medicines such
as ACE, NSAIDs and Cox-2 inhibitors that contribute to declining
renal function. Antituberculosis medicines and alcohol affect liver
function. It is important to regularly monitor renal and liver function,
especially when such medicines are needed.
The medicine regimen should be reviewed every time a medicine is
started or stopped, an adverse event occurs or health status changes.
An admission to hospital is an ideal time to undertake a medicines
review and assess their understanding of their medicines and their
medicine self-management capacity. Admission and discharge
between wards/units and between care settings are high risk times:
medicine reconciliation should occur at every transition [12,13].
The general practitioner and other carers can contribute important
information to medicine reviews and should be informed about the
outcome of any medicine review and changes to the medicine
regimen. The medicines review must include complementary and
alternative therapies (CAM) because people with diabetes are high
CAM users [34]: some CAM are beneficial, safe non-medicine options.
Quality use of medicines (QUM) [35] is a useful framework for
using the information from comprehensive assessments to make
decisions about the medicine regimen, doses and dose frequency.
Importantly, QUM encompasses the entire medicine pathway (from
bench to bedside), regulatory processes, labeling, and advocates using
non-medicine options when they are safe and evidence-based.
Several decision support tools are available to help health
professionals manage medicines for/with older people. These include:
BEERS criteria [15]
Screening Tool to Alert doctors to the Right Treatment (START)
[22]
Screening Tool of Potentially inappropriate Prescriptions (STOPP)
[23]
Medication Appropriateness Index (MAI) [36]
Australian Inappropriate Medication Use and Prescribing
Indicators Tool [36,37]
Guidelines such as National Institute of Clinical Excellence (NICE)
[38], National Prescribing Service (NPS) [24] The McKellar Guidelines
[4] and the International Federation Global Guideline for Managing
Older People with Type 2 Diabetes [3].
Various medicine AE risk assessment tools such as Medicines Risk
Screen (NPS) [39], the GLM-related Adverse Event Risk Assessment
Tool [4].
High Risk Medicine Alerts [32].
However, it is essential to prescribe medicines appropriate for the
individual’s clinical context when using these decision aids and alerts.
Making decisions in collaboration with the multidisciplinary team
facilitates appropriate in dividualised prescribing [3,4,12,13]. Where
possible the individual is involved in such decisions to enhance
medicines self-care.
These lists focus on high risk medicines but many AEs and side
effects are due to commonly prescribed and self-prescribe medicines,
not on lists such as BEERs. Miller et al. [40] reported 11.6% of people
had at least one AE in the preceding six months, most of which were
mild to moderate; 11.8 were severe and 5.4% required a hospital
admission as a result of using 13 commonly prescribed medicines not
on lists such as BEERS Criteria [15,16]. These tools were developed to
aid medicine prescribing decisions, not replace reasoned clinical
decision-making. However, STOPP does help identity possibly
avoidable AEs [41]. Some decision support tools are not appropriate
for every country because they list medicines not commonly used or
available in some countries [37].
Conclusion
Enhancing the knowledge and competence of health professionals,
older people with diabetes and other careers responsible for managing
medicines with/for older people is essential [3,4,5]. Health
professionals responsible for managing older people with diabetes
must understand the pharmacology of, warnings about and
contraindications to commonly used GLMs and where to access
reputable medicines information.
They must also be alert to the emerging importance of diabetes-
related cognitive change and mood disturbances that have profound
effects on adherence to treatment and the ability to achieve safe,
effective targets. Many health and social care professionals also
provide care for frail vulnerable older people; thus, it is reasonable to
suggest that understanding the concept of frailty could help optimise
prescribing for older people. Incorporating frailty measures into future
clinical studies of medicine effects and pharmacokinetics is important
if we are to improve medication use and guide medicine doses
appropriate for frail older people [43].
Older people have often lived with their diabetes for many years
and are ‘experts in their diabetes’, consequently many functionally
independent older people want to be involved in care decisions [44].
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Personalized medicine education is more effective than ‘standard’
education that does not take account of the individual’s personal risk
factors, literacy level and other needs and/or the needs of family and
other careers. There are many reputable on-line sources of
information is as well as phone apps that can help people manage their
diabetes and medicines safely. Generally a combination of written and
verbal information is desirable [45].
It is important to identify individual factors that lead to medicine
non-adherence such as polypharmacy, misinterpreting medicine side
effects, not understanding the ‘directions for use,’ medicine beliefs and
attitudes, costs, and access. Tools such as the Brief Medicine
Questionnaire, Medicine Adherence Report (MARS) and the Beliefs
about Medication Questionnaire (BaMQ) [4]. The Morisky
Medication Adherence Scale [46] can be used to determine non-
adherence but it has low validity and uses judgemental language.
QUM and pharmocovigilance have their basis in ethical patient
care. Health professionals have a duty of care to deliver safe, ethical
care and ‘first do no harm.’ Ensuring the environment in which health
professionals manage medicines has relevant infrastructure to actively
support patient safety generally and for medicines in particular. The
infrastructure should include accessible medicine guidelines and
polices in place to support pharmocovigilance. For example,
automated alerts to medicine allergies, hypoglycaemia risk, CAM
medicine use, and prescribed HRMs. Currently, hypoglycaemia risk
and CAM use are not standard medicine alerts. Medicine lists for
people with diabetes can be helpful if they are kept current and
communicated among health professionals caring for the individual,
especially prescribers. Usually a combination of methods is more
effective than single strategies [45].
It is more difficult to identify health professional- related factors
that lead to inappropriate prescribing. Some factors include
inadequate communication multiple prescribers, knowledge deficits
and ageist attitudes. Older physician are less likely to follow guidelines
or prescribe newer medicines for various reasons [46]. It is likely these
traits also occur in other health professional disciplines.
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